Observational studyPloS one2017

Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting.

Amy P Abernethy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.